ILMN Stock Set to Gain From Latest Updates to the NovaSeq X Series Jan. 8, 2025 at 6:58 a.m. ETon Zacks.com $100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today Jan. 7, 2025 at 11:45 a.m. ETon Benzinga.com ...
做生命科学投资的同学一定都知道基因检测龙头$Illumina(ILMN)$7年15倍的传奇故事,错过的一定后悔不已。现在有更好的机会就在眼前,看看我们是否能抓住了! 7年15倍,多么惊艳的曲线-- ILMN 在创立ILMN对基因检测技术革命后,抱着要对作为生命基础的蛋白质检测技术进行革命的使命,12年前ILMN的创始人之一技术大拿David ...
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship b...
Intra-Cellular Therapies has an analyst consensus of Strong Buy, with a price target consensus of $95.31, representing a 25.3% upside. In a report issued on June 12, J.P. Morgan also maintained a Buy rating on the stock with a $78.00 price target. See today’...
which include stock-based compensation. I encourage you to review the GAAP reconciliation of these non-GAAP measures, which can be found in today’s release and in supplementary data available on our website. In the second quarter, consolidated revenue was $1.16 billion, up 3% year-over-year...
Stock Price$136.22 Change1.08% Volume1,363,470 Illumina, Inc. is developer, manufacturer and marketer of integrated systems for the large scale analysis of genetic variation and biological function. Request Video of ILMN Already a member?